Keyword: Memorial Sloan-Kettering Cancer Center
CAR-T has seen a host of successes in blood cancers, but translating that into solid tumors has proven much more difficult.
A new assay that combines Illumina's ultradeep sequencing with Grail's machine-learning algorithm could detect multiple targetable cancer mutations.
Digital pathology startup Paige.AI has received a breakthrough device designation from the FDA for its use of AI in the diagnosis of cancer.
Boehringer’s Corsico jumps to head dev at GSK; Kite’s Polverino takes CSO role at Zymeworks; and Kymera taps former Alnylam executive as CMO.
Baselga framed his resignation as an attempt to stop the news from becoming a distraction for MSK.
José Baselga, M.D., a top cancer researcher, did not disclose his ties to industry in academic papers about 60% of the time since 2013.
A drug that blocks heat shock protein 90 (HSP90) offer a new way of treating an aggressive form of leukemia.
Two new studies suggest that blocking the cytokine IL-1 with a rheumatoid arthritis drug could treat neurological side effects of CAR-T treatments.
Preclinical-stage biotech Abpro Therapeutics wants to trial its two lead candidates for HER2-positive cancers and diabetic macular edema in 2019.
Memorial Sloan Kettering Cancer Center’s Maura Dickler, M.D., has been lined up as Lilly’s new VP of late-phase development in oncology.